医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ImpediMed Announced Medicare Payment for New L-Dex® Category I Code

2014年11月03日 PM08:00
このエントリーをはてなブックマークに追加


 

BRISBANE, Australia & SAN DIEGO

ImpediMed (ASX:IPD) is pleased to announce today the Centers for Medicare and Medicaid Services (CMS) has published the valuation for CPT® Category I Code 93702 for the Company’s L-Dex procedure for the assessment of lymphedema.

Beginning January 1, 2015, physicians and hospitals will be able to seek reimbursement for the L-Dex procedure through this new CPT Category I code. CMS has assigned CPT code 93702 to the Outpatient Ambulatory Payment Classification (APC) payment group 0097, which has a 2015 payment rate of $112.67 when billed by a hospital outpatient facility. Physician payment is based on “relative value units” (RVUs). CMS has assigned 3.21 RVUs to the L-Dex CPT Code (code 93702) resulting in an average national physician payment rate of $114.99.

Release of the valuation for the Category I code for L-Dex is another major reimbursement milestone, and should provide greater access for patients, facilitate claims processing and accelerate coverage from payers.

Mr. Richard Carreon, CEO of ImpediMed said, “The publication of this CPT Category I code valuation is a significant milestone and will be central to driving market adoption of L-Dex. We are pleased that today’s announcement means that many US cancer patients will have access to this important test. Our targeted launch begins in January 2015 and we are now armed with both compelling clinical evidence and a simplified, standardized reimbursement environment for physicians.

ImpediMed’s L-Dex product utilizes proprietary bioimpedance spectroscopy (BIS) technology, allowing it to more accurately measure fluid status than the competitive tools commonly used. BIS also enables a more timely diagnosis of lymphedema, which affects roughly 1 in 3 cancer patients. The clinical implications of fluid burden are significant, especially for cancer patients, for whom lymphedema has become a primary contributor to adverse outcomes, increased hospitalization, and increased mortality.

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com

CONTACT

For further information contact:
ImpediMed Limited
Richard
Carreon, +1 (760) 585-2100
CEO
Morten Vigeland, +1 (760)
585-2100
CFO

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent